“A big, headline-grabbing company is not always your best bet, assuming you’re a shrewd investor seeking to maximize your profits,” advises the author of today’s article – and this may be especially true when it comes to biotech stocks. What two “size benefits” do smaller companies have – and why does the “size factor” work? CLICK HERE.
“I think this is the ground floor of a market that could be worth more than $29 billion by the end of the decade,” declares the author of today’s article of the “New Biotech” sector he discusses: psychedelics. For more on the potential profit opportunities associated with the “Shroom Boom” – especially in light of recent news regarding an important, successful FDA…
When it comes to what makes a good tech company – and the secret to investing in the right one – the author of today’s article declares the following: “There’s one rule that I follow when investing in tech, and it’s served me well over my entire career…” What is this rule – and the secret to investing in tech?…
“These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential,” says the author of today’s article of the five stocks he highlights, all of which are smaller-cap tech companies trading under the $10 level. For these five tech stocks, CLICK HERE.
“The best big pharma stocks offer growth potential thanks to strong pipelines, steady income with dependable dividends, and the opportunity to invest in a business that can make a huge positive impact in the lives of millions of people,” advises the author of today’s article, who proceeds to highlight three such pharma stocks that may be among the best picks…
A new approach is evolving for the treatment of cancer, which, as today’s article explains, involves “discovering pairs of genes whose combined activity is vital to cancer cells, allowing a joint attack to kill tumors in a strategy known as ‘synthetic lethality’”. For a look at two startups focused on finding cancer’s combined weaknesses – and with drug candidates entering…
Despite its focus on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases, the clinical-stage company featured in today’s article is woefully behind the likes of Pfizer, Moderna, Johnson & Johnson and AstraZeneca when it comes to its COVID-19 product – its lead product. But the real value for this company may come from another product…
With new leadership at the federal agencies that oversee the drug industry, a top Wall Street analyst is warning that the biotech industry and biotech investors “will need to adjust to a different regulatory environment to the one they have enjoyed for the last 5 years” – and has downgraded six pharma stocks due, in part, to the prospect of…
Thanks to her bet on disruptive DNA, Bloomberg named ARK Investment Management’s Cathie Wood the best stock picker of 2020. What does Wood believe are going to be the most disruptive sectors going forward, and what specific companies are working on truly disruptive technologies with the potential to change the course of history? For more – including a look at…
When it comes to creating a useful profile for monster growth stocks, the author of today’s article lays out the following criteria: “gangbusters gains, Buy ratings from the Wall Street analyst corps, and considerable upside for the coming year.” With that, he proceeds to highlight three stocks that meet the profile for monster growth, including one that “puts a different…